Tasso Releases New Tech for Dried Blood Spot Sample Collection

Tasso Inc. has launched its next-generation technology for dried blood spot (DBS) sample collection, which combines the company’s new Tile-T20 dried whole blood cartridge with a Tasso Mini device, thereby enabling precise, convenient DBS sample collection for clinical trials and sports anti-doping testing.

“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples,” Tasso Co-Founder/CEO Ben Casavant, Ph.D., said. “Our next-generation dried blood collection systems enable a better patient experience alongside new process improvements.”

Tasso’s new collection system provides advantages over legacy DBS methods, improving and accelerating the clinical trial process, according to the company. Tile-T20 is the first DBS collection cartridge designed specifically for use with patient-centric blood lancets. Tile-T20 collects four precise, volumetrically-controlled blood samples that meet the needs of quantitative endpoints or drug concentration measurements. It is compatible with any of Tasso’s virtually painless, U.S. Food and Drug Administration (FDA)-cleared and CE Marked blood collection devices, including Tasso Mini and Tasso+.

Tasso Mini is the latest device in Tasso’s signature line of patient-centric blood lancets, providing a gentle collection experience ideal for use with sensitive populations or for applications that may require more frequent blood draws. The Tasso Mini device is FDA Class II Lancet 510(k)-cleared and CE Marked.

“Access to clinic sites can be difficult for many patients, especially for those without reliable transportation or living in rural areas. Unfortunately, access challenges often lead to recruitment and retention issues, ultimately delaying clinical trial timelines,” Tasso Co-Founder/Chief Technology Officer Erwin Berthier, Ph.D., stated. “This new technology has the potential to improve trial timelines and speed new therapies to patients in need.”

Tasso is an emerging healthcare technology company striving to transform the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Headquartered in Seattle, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders.